

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Aptus Pharma Ltd. Connecting...Life

APTUS PHARMA LIMITED

CIN: U24230GJ2010PLC061957

Our Company was originally incorporated as "Aptus Pharma Private Limited", as a private limited company under the Companies Act, 1956, with the Registrar of Companies ("ROC"), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of our Company was changed to "Aptus Pharma Limited" and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. For further details please refer to chapter titled "History and Certain Corporate Matters" beginning on Page No. 161 of this Draft Red Herring Prospectus.

Registered Office: Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427. Corporate Office: SHREE Building 1st Floor Opp Satyasaal Heart Hospital, Narayan Nagar Kalawad Road, Rajkot Sau Uni Area Rajkot, Gujarat, 360005

Telephone: +91 76004 27827; Email: info@aptuspharma.com; Website: www.aptus-pharma.com; Contact Person: Mohini Hardik Gandhi, Company Secretary and Compliance Officer;

OUR PROMOTERS: TEJASH MAHESHCHANDRA HATHI, CHATRABHUI VALLABHAI BUTANI, KAPILBHAI HASMUKHBHAI CHANDARANA, GHANSHYAM VINUBHAI PANSURIYA, MILLY CHETAN LALSETA, RIDDHISH NATWARLAL TANNA, GAURANG RAMESHCHANDRA THAKKER, KRIPALIBEN MAYANK THAKKER AND KUNJAL PIYUSHBHAI UNADKAT

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED."

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 20,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF APTUS PHARMA LIMITED (THE "COMPANY" OR "APTUS" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [-] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [-] ("THE ISSUE"), OF WHICH [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [-] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE AGGREGATING TO ₹ [-] WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E., NET ISSUE OF [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [-] PER EQUITY SHARE AGGREGATING TO ₹ [-] LACS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [-] % AND [-] % RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [-] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [-] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND [-] (A WIDELY CIRCULATED GUJARATI NATIONAL DAILY NEWSPAPER) WHERE OUR REGISTERED OFFICE IS LOCATED, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE SME") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing under the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI (ICDR) Regulations, as amended, wherein [-] (not more than 50% of the Net Issue) shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, [-] (not less than 15% of the Net Issue) shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and upto such lots equivalent to not more than ₹ 10 lakhs and (b) two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs provided under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion and [-] (not less than 35% of the Net Issue) shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders other than Anchor Investors, are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of IIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCBS or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 275 of this Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the offer and DRHP dated June 18, 2025 which has been filed with the SME Platform of BSE Limited.

Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the SME Platform of BSE Limited (BSE SME) shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE at https://www.bsesme.com/download/341484/SME_IP0%20inPrinciple/DRHP_Aptus_20250618225336.pdf and the website of the Company at www.aptus-pharma.com, and at the website of BRLM i.e. INTERACTIVE FINANCIAL SERVICES LIMITED at www.ifinservices.in. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the SME Platform of BSE Limited (BSE SME) with respect to disclosures made in DRHP. The members of the public are requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by BSE, and/or our Company and/or our Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the offer on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 26 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 60 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "Our History and Certain Other Corporate Matters" beginning on page 161 of the Draft Red Herring Prospectus.

Table with 3 columns: LEAD MANAGER OF THE ISSUE, REGISTRAR TO THE ISSUE, COMPANY SECRETARY AND COMPLIANCE OFFICER. Includes details for Interactive Financial Services Limited, Bigshare Services Private Limited, and Mohini Hardik Gandhi.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP. For APTUS PHARMA LIMITED On Behalf of the Board of Directors Sd/- Mohini Hardik Gandhi Company Secretary and Compliance Officer

Disclaimer: APTUS PHARMA LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on June 18, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bsesme.com/PublicIssues/SMEIPDRHP.aspx#... offer and is available on the websites of the BRLM at www.ifinservices.in and also on the website of the Company www.aptus-pharma.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 26 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

VEGORAMA PUNJABI ANGITHI LIMITED. CIN: U55101DL2022PLC395857. Our Company was originally incorporated as a Private Limited Company under the name of "Vegorama Punjabi Angithi Private Limited" on March 30, 2022 under the provisions of the Companies Act, 2013 with the Registrar of Companies, NCT of Delhi. Subsequently our Company was converted into Public Limited pursuant to resolution passed by our shareholders at Extra ordinary general meeting held on March 05, 2025 and a fresh Certificate of Incorporation pursuant to conversion into public limited dated April 09, 2025 issued by the Registrar of Companies, Central Processing Centre. For details of incorporation, change of registered office of our Company, please refer to the section titled "History and Corporate Structure" on page no. 192 of this Draft Red Herring Prospectus.

Registered Office: B-376, Third Floor, Meera Bagh, Outer Ring Road, Paschim Vihar, New Delhi- 110063. Telephone: +91-11-46112637; Website: www.punjabiangithi.in; E-mail: compliance@punjabiangithi.in. Company Secretary and Compliance Officer: Ms. Karuna Sharma. OUR PROMOTER: MR. DEEPAK CHADHA

INITIAL PUBLIC ISSUE OF UP TO 49,84,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF VEGORAMA PUNJABI ANGITHI LIMITED FOR CASH AT A ISSUE PRICE OF ₹ [-] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ [-] PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ [-] LAKHS COMPRISING OF FRESH ISSUE OF UP TO 39,87,200 EQUITY SHARES AGGREGATING TO ₹ [-] LAKHS ("FRESH ISSUE") AND AN OFFER FOR SALE OF UPTO 9,96,800 EQUITY SHARES BY MR. DEEPAK CHADHA ("SELLING SHAREHOLDER") AGGREGATING TO ₹ [-] LAKHS ("OFFER FOR SALE") ("THE ISSUE") AND UPTO 2,51,200 EQUITY SHARES AT AN ISSUE PRICE OF ₹ [-] PER SHARE AGGREGATING TO ₹ [-] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF UP TO 47,32,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE AGGREGATING TO ₹ [-] LAKHS ("NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30% AND 28.49% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. PLEASE REFER TO SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO. 281 OF THIS DRAFT RED HERRING PROSPECTUS.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders, out of which (a) one third of such portion was reserved for applicants with application size of more than 2 lots and up to such lots equivalent to not more than 10,00,000 and (b) two-third of such portion was reserved for applicants with application size of more than 10,00,000 provided that the unsubscribed portion in either of such subcategories could have been allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, Equity Shares capital will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of IIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCBS or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For further details please refer the section titled "Issue Procedure" beginning on page no. 298 of this Draft Red Herring Prospectus. Provided further that for the purpose of public issue by an issuer to be listed on SME exchange made in accordance with Chapter IX of these regulations, the words "Retail Individual investors" shall be read as words "Individual Investors who applies for minimum application size" A copy will be filed with the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS [-] TIMES OF THE FACE VALUE

This public announcement is being made in compliance with and in accordance with SEBI press release no. PR No. 36/2024 dated December 18, 2024 (208) SEBI Board meeting on "Review of SME framework under SEBI (ICDR) Regulations, 2018, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies) to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and has filed the Draft Red Herring Prospectus dated June 18, 2025 which has been filed with the SME Platform of BSE Limited ("BSE SME" or "BSE"). In relation to above, the Draft Red Herring Prospectus filed with BSE shall be made available to the public for comments, if any, for a period of at least 21 days, from the date mentioned below by hosting it on the respective websites of the Stock Exchange i.e., BSE at www.bseindia.com, website of the Company at www.punjabiangithi.in and the websites of the Book Running Lead Manager to the Issue at www.corporatemakers.in. Our Company hereby invites the members of the public to give comments on the Draft Red Herring Prospectus filed with BSE with respect to disclosures made in the Draft Red Herring Prospectus. The members of the public are requested to send a copy of their comments to BSE and/or to the Company Secretary and Compliance Officer (compliance@punjabiangithi.in) of our Company and/or the Book Running Lead Manager of the Issue at their respective addresses mentioned herein below in relation to the issue on or before 5:00 PM, on the 21st day i.e. 21 days from the date of filing of "Issue Document with SME Platform of BSE Limited ("BSE SME).

Investment in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this issue. For taking an investment decision, investors must rely on their own examination of the issuer and this Issue; including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the statement of "Risk Factors" given on page 30 of the Draft Red Herring Prospectus. Any decision to invest in the Equity Shares described in the Draft Red Herring Prospectus may only be made after the Red Herring Prospectus has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus.

The Equity Shares, when offered, through the Red Herring Prospectus, and proposed to be listed on the SME Platform of BSE Limited ("BSE SME" or "BSE"). For details of the main objects of our Company as contained in its Memorandum of Association, see "History and Corporate Structure" on page 192 of the Draft Red Herring Prospectus.

The liability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 72 of the Draft Red Herring Prospectus.

Table with 2 columns: CORPORATE MAKERS CAPITAL LIMITED and BIGSHARE SERVICES PRIVATE LIMITED. Includes contact details for both entities.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed in the Draft red herring Prospectus.

For Vegorama Punjabi Angithi Limited On behalf of the Board of Directors Sd/- Karuna Sharma Company Secretary and Compliance Officer

Vegorama Punjabi Angithi Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus with BSE on June 18, 2025. The Draft Red Herring Prospectus shall be available on the website of the BSE at www.bseindia.com and is available on website of the Company i.e. www.punjabiangithi.in, website of the Lead Manager to the issue, Corporate Makers Capital Limited at www.corporatemakers.in. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 30 of the Draft Red Herring Prospectus and the details set out in the Prospectus, when filed. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States under the U.S. Securities Act of 1933 or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, the securities described in this announcement are not being offered or sold in the United States.

Wheels India Limited. CIN: U55021HR90PLC004175. Registered Office: No. 21, Padma Road, Chennai - 600 022. Tel: (94) 40327476. Email: investor@wheelsindia.com. NOTICE TO SHAREHOLDERS: Mandatory Transfer of Equity Shares of the Company to the Investor Education and Protection Fund (IEPF).

This Notice is published pursuant to Section 124(6) of the Companies Act, 2013 and Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 read with relevant circulars and amendments thereto ("IEPF Rules"). The Company is mandated to transfer all shares in respect of which dividend(s) have not been paid or claimed for seven consecutive years to the Investor Education and Protection Fund Authority ("IEPF Authority").

The Company has communicated individually to the concerned shareholders whose shares are liable to be transferred to IEPF Authority in case those who have not e-cashed any of their dividend(s), remaining unpaid / unclaimed for last seven (7) consecutive years, by the next due date of transfer i.e. September 19, 2025. The details of such shareholders including their folio number or DP and Client ID and number of shares due for transfer are also available on the Investors section of the Company's website at www.wheelsindia.com.

The concerned shareholders have been advised to make their claim latest by September 19, 2025 for the unclaimed dividends in respect of shares held by them in writing to the Company or to the Company's Registrar and Share Transfer Agent, M/s. Cameo Corporate Services Limited, "Subramanian Building", No. 1, Club House Road, Chennai - 600002; Telephone: 044-28460390/91/92/93/94; e-mail ID: investor@cameoindia.com. If the Company does not receive any communication from the concerned shareholders, the Company, shall with a view to complying with the requirements set out in the Rules, dematerialize and transfer the shares to the IEPF Authority by way of corporate action by the due date as per the procedure stipulated in the said Rules.

FIDELITY MARKET & FINCAP PRIVATE LIMITED. CIN:U51909WB1994PTC062119. Marshall House, 33/1, Netaji Subhas Road, 5th Floor, Room No.: 562, Kol-700001. Tel. Ph.: 9830051685, E-mail : jhunjhunwalacompliance@gmail.com

PUBLIC NOTICE. In compliance with the circular no. DNBS (DD)/CC.No.11/02. 01/99-2000 issued by the Reserve Bank of India on 15.11.1999 as amended from time to time, Notice is hereby given that subject to compliance of such requisite formalities and fulfillment of such conditions, if any, required by Reserve Bank of India (RBI) or any other competent authority and prior approval of RBI taken as per Circular No. DNBS(PD). CC.No.376/03. 10.001/2013-14 dt.26.05.2014, DNBR(PD).CC.NO.065/03.10.001/2015-16 dt. 09.07.2015, in terms of para 42 of Master Direction-Non-Banking Financial Company Scale Based Regulations-DoR.FIN. REC.No.45/03. 10.119/2023-24. dt. 19.10.2023 and prior approval obtained vide letter No KOL.DOR.No.S236/01-01-005/2025-2026, the change of directorship and management of M/s. Fidelity Market & Fincap Private Limited, an existing Non-Banking Finance Company (herein referred to as "the Company") of Marshall House, 33/1, Netaji Subhas Road, 5th Floor, Room No. 562, Kolkata - 700001 will be changed by appointment of new director, Mr. Dhruv Jhunjhunwala of 12C, Chakraborty Road (N), Manglam Apartment, Kolkata - 700020, by occupation Business and after the change the new composition of Board of Directors comprised of Mr. Dhruv Jhunjhunwala, Mr. Siddhartha Jhunjhunwala, Mr. Shyam Sundar Dhelia. The Main purpose of the change will be resulted to ensure continuity and effective management and strengthen & broad base the present Non-Banking Financial activities of the Company. Any person whose interest is likely to be affected by the change may intimate to the new composition of Board of Directors, the existing composition of Board of Directors or the Company at the above mentioned address and the Reserve Bank of India, DOS,15, N. S. Road, 5th Floor, Kolkata 700001 within 30 days from the date of publication of this notice stating therein the nature of interest and ground of objection. Issued by the new composition of Board of Directors, the existing composition of Board of Directors or the Company above named.

M/s. Fidelity Market & Fincap Pvt. Ltd. Sd Shyam Sundar Dhelia (Director) DIN:03573394

KMF Karnataka Co-Operative Milk Producers' Federation Limited. KMF Complex, Dr M H Marigowda Road, Bangalore-560029. Phone : 26096832 / 910 Fax : 080-25536105 E'mail : purchase@kmf.coop. IFT No. KMF/PUR/Tender-794/2025-26 Date: 19.06.2025

TENDER NOTIFICATION (KMF/2025-26/SE3601) (Through KP Procurement Portal)

The Karnataka Milk Federation Ltd., Bangalore invites tenders from eligible tenderers for the Hiring of Dry Godown for storage of Milk powder for detailed below for a period two years:

Table with 3 columns: Sl. No., Item, EMD. Row 1: 01, Hiring of Dry Godown for storage of Milk powder for a period two years, 80,000/-

Tender Document may be downloaded from e-procurement website https://kppp.karnataka.gov.in. Tenderers may submit tenders on or before 03.07.2025 up to 5.00 pm. Other details can be seen in the tender document.

For Karnataka Co-Op. Milk Federation Ltd., Sd/- DIRECTOR (PURCHASE)

Advertisement for The Indian Express. Features a portrait of a man and the text: "I look at every side before taking a side. Inform your opinion with insightful perspectives." The Indian Express logo and tagline "JOURNALISM OF COURAGE" are also present.

indianexpress.com